西罗多辛在治疗男性前列腺良性增生下尿路症状中的应用:“现实生活”中的标准方法和应用

Q4 Medicine
A. Alcántara Montero
{"title":"西罗多辛在治疗男性前列腺良性增生下尿路症状中的应用:“现实生活”中的标准方法和应用","authors":"A. Alcántara Montero","doi":"10.1016/j.uromx.2016.09.005","DOIUrl":null,"url":null,"abstract":"<div><p>Lower urinary tract symptoms (LUTS) are very frequent in men, especially in those above 65 years of age. Benign prostatic hyperplasia (BPH) is the pathology most associated with LUTS in men and is a frequent cause of altered quality of life. Monotherapy with alpha blockers is the treatment of choice in patients with moderate-to-severe LUTS secondary to BPH.</p><p>Silodosin is currently the most uroselective alpha blocker acting on the α1A receptors. Its uroselectivity has been confirmed in different <em>in vitro</em>, as well as <em>in vivo</em>, studies. The present study analyzed the main benefits of silodosin in phase <span>iii</span> clinical trials (standard approach) and in «real life» (analyzing the «Silodosin in Real-life Evaluation (SiRE)» phase <span>iv</span> trial) to validate the registrational trials and confirm the positive risk-benefit profile of silodosin in an environment that can more closely reflect clinical practice.</p></div>","PeriodicalId":34909,"journal":{"name":"Revista mexicana de urologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uromx.2016.09.005","citationCount":"1","resultStr":"{\"title\":\"Silodosina en el tratamiento de los síntomas del tracto urinario inferior en el varón por hiperplasia benigna de próstata: enfoque estándar y uso en la «vida real»\",\"authors\":\"A. Alcántara Montero\",\"doi\":\"10.1016/j.uromx.2016.09.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Lower urinary tract symptoms (LUTS) are very frequent in men, especially in those above 65 years of age. Benign prostatic hyperplasia (BPH) is the pathology most associated with LUTS in men and is a frequent cause of altered quality of life. Monotherapy with alpha blockers is the treatment of choice in patients with moderate-to-severe LUTS secondary to BPH.</p><p>Silodosin is currently the most uroselective alpha blocker acting on the α1A receptors. Its uroselectivity has been confirmed in different <em>in vitro</em>, as well as <em>in vivo</em>, studies. The present study analyzed the main benefits of silodosin in phase <span>iii</span> clinical trials (standard approach) and in «real life» (analyzing the «Silodosin in Real-life Evaluation (SiRE)» phase <span>iv</span> trial) to validate the registrational trials and confirm the positive risk-benefit profile of silodosin in an environment that can more closely reflect clinical practice.</p></div>\",\"PeriodicalId\":34909,\"journal\":{\"name\":\"Revista mexicana de urologia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.uromx.2016.09.005\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista mexicana de urologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2007408516300726\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista mexicana de urologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2007408516300726","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

下尿路症状(LUTS)在男性中非常常见,尤其是65岁以上的男性。良性前列腺增生(BPH)是与男性LUTS最相关的病理,也是生活质量改变的常见原因。α受体阻滞剂单药治疗是BPH继发的中重度LUTS患者的治疗选择。西洛多辛是目前作用于α1A受体的泌尿选择性最强的α受体阻滞剂。其尿选择性已在不同的体外和体内研究中得到证实。本研究分析了西洛多辛在iii期临床试验(标准方法)和“现实生活”(分析“西洛多辛在现实生活中的评估(SiRE)”iv期试验)中的主要益处,以验证注册试验,并确认西洛多辛在更能反映临床实践的环境中的积极风险-收益概况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Silodosina en el tratamiento de los síntomas del tracto urinario inferior en el varón por hiperplasia benigna de próstata: enfoque estándar y uso en la «vida real»

Lower urinary tract symptoms (LUTS) are very frequent in men, especially in those above 65 years of age. Benign prostatic hyperplasia (BPH) is the pathology most associated with LUTS in men and is a frequent cause of altered quality of life. Monotherapy with alpha blockers is the treatment of choice in patients with moderate-to-severe LUTS secondary to BPH.

Silodosin is currently the most uroselective alpha blocker acting on the α1A receptors. Its uroselectivity has been confirmed in different in vitro, as well as in vivo, studies. The present study analyzed the main benefits of silodosin in phase iii clinical trials (standard approach) and in «real life» (analyzing the «Silodosin in Real-life Evaluation (SiRE)» phase iv trial) to validate the registrational trials and confirm the positive risk-benefit profile of silodosin in an environment that can more closely reflect clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revista mexicana de urologia
Revista mexicana de urologia Medicine-Urology
CiteScore
0.20
自引率
0.00%
发文量
49
期刊介绍: Revista Mexicana de Urología (RMU) [Mexican Journal of Urology] (ISSN: 0185-4542 / ISSN electronic: 2007-4085) is bimonthly publication that disseminates research by academicians and professionals of the international medical community interested in urological subjects, in the format of original articles, clinical cases, review articles brief communications and letters to the editor. Owing to its nature, it is publication with international scope that disseminates contributions in Spanish and English that are rigorously reviewed by peers under the double blind modality. Neither journalistic documents nor those that lack rigorous medical or scientific support are suitable for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信